Cryopyrin-Associated Periodic Syndrome (CAPS) - Pipeline Insight, 2021
![](/report_cover/8047/cryopyrin-associated-periodic-syndrome-caps-pipeline-insight-2021_en.gif)
This report can be delivered to the clients within 24 Hours
DelveInsight’s, “Cryopyrin-Associated Periodic Syndrome (CAPS) - Pipeline Insight, 2021,” report provides comprehensive insights about 3+ companies and 3+ pipeline drugs in Cryopyrin-Associated Periodic Syndrome (CAPS) pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Geography Covered
Cryopyrin-Associated Periodic Syndrome (CAPS): Overview
Cryopyrin-associated periodic syndrome or syndromes (CAPS), also known as cryopyrinopathies, are genetic autoinflammatory syndromes defined by ‘gain-of-function’ mutations affecting the cryopyrin protein. Cryopyrin-associated periodic syndromes are all autosomal dominant genetic conditions, meaning only one copy of the abnormal gene is required to develop the clinical syndrome. CAPS comprises 3 disorders on a continuum of severity: severe CINCA syndrome, intermediate Muckle-Wells syndrome (MWS) and milder familial cold urticaria (FCAS).
'Cryopyrin-Associated Periodic Syndrome (CAPS) - Pipeline Insight, 2021' report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Cryopyrin-Associated Periodic Syndrome (CAPS) pipeline landscape is provided which includes the disease overview and Cryopyrin-Associated Periodic Syndrome (CAPS) treatment guidelines. The assessment part of the report embraces, in depth Cryopyrin-Associated Periodic Syndrome (CAPS) commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Cryopyrin-Associated Periodic Syndrome (CAPS) collaborations, licensing, mergers and acquisition, funding, designations and other product related details.
Report Highlights
This segment of the Cryopyrin-Associated Periodic Syndrome (CAPS) report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Cryopyrin-Associated Periodic Syndrome (CAPS) Emerging Drugs
Further product details are provided in the report……..
Cryopyrin-Associated Periodic Syndrome (CAPS): Therapeutic Assessment
This segment of the report provides insights about the different Cryopyrin-Associated Periodic Syndrome (CAPS) drugs segregated based on following parameters that define the scope of the report, such as:
Cryopyrin-Associated Periodic Syndrome (CAPS): Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Cryopyrin-Associated Periodic Syndrome (CAPS) therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Cryopyrin-Associated Periodic Syndrome (CAPS) drugs.
Cryopyrin-Associated Periodic Syndrome (CAPS) Report Insights
Current Treatment Scenario and Emerging Therapies:
DelveInsight’s, “Cryopyrin-Associated Periodic Syndrome (CAPS) - Pipeline Insight, 2021,” report provides comprehensive insights about 3+ companies and 3+ pipeline drugs in Cryopyrin-Associated Periodic Syndrome (CAPS) pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Geography Covered
- Global coverage
Cryopyrin-Associated Periodic Syndrome (CAPS): Overview
Cryopyrin-associated periodic syndrome or syndromes (CAPS), also known as cryopyrinopathies, are genetic autoinflammatory syndromes defined by ‘gain-of-function’ mutations affecting the cryopyrin protein. Cryopyrin-associated periodic syndromes are all autosomal dominant genetic conditions, meaning only one copy of the abnormal gene is required to develop the clinical syndrome. CAPS comprises 3 disorders on a continuum of severity: severe CINCA syndrome, intermediate Muckle-Wells syndrome (MWS) and milder familial cold urticaria (FCAS).
'Cryopyrin-Associated Periodic Syndrome (CAPS) - Pipeline Insight, 2021' report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Cryopyrin-Associated Periodic Syndrome (CAPS) pipeline landscape is provided which includes the disease overview and Cryopyrin-Associated Periodic Syndrome (CAPS) treatment guidelines. The assessment part of the report embraces, in depth Cryopyrin-Associated Periodic Syndrome (CAPS) commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Cryopyrin-Associated Periodic Syndrome (CAPS) collaborations, licensing, mergers and acquisition, funding, designations and other product related details.
Report Highlights
- The companies and academics are working to assess challenges and seek opportunities that could influence Cryopyrin-Associated Periodic Syndrome (CAPS) R&D. The therapies under development are focused on novel approaches to treat/improve Cryopyrin-Associated Periodic Syndrome (CAPS).
This segment of the Cryopyrin-Associated Periodic Syndrome (CAPS) report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Cryopyrin-Associated Periodic Syndrome (CAPS) Emerging Drugs
- DFV 890: Novartis
- IZD334: Inflazome
Further product details are provided in the report……..
Cryopyrin-Associated Periodic Syndrome (CAPS): Therapeutic Assessment
This segment of the report provides insights about the different Cryopyrin-Associated Periodic Syndrome (CAPS) drugs segregated based on following parameters that define the scope of the report, such as:
- Major Players in Cryopyrin-Associated Periodic Syndrome (CAPS)
- Phases
- Late stage products (Phase III)
- Mid-stage products (Phase II)
- Early-stage product (Phase I) along with the details of
- Pre-clinical and Discovery stage candidates
- Discontinued & Inactive candidates
- Route of Administration
- Oral
- Parenteral
- intravenous
- Subcutaneous
- Topical.
- Molecule Type
- Monoclonal Antibody
- Peptides
- Polymer
- Small molecule
- Gene therapy
- Product Type
Cryopyrin-Associated Periodic Syndrome (CAPS): Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Cryopyrin-Associated Periodic Syndrome (CAPS) therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Cryopyrin-Associated Periodic Syndrome (CAPS) drugs.
Cryopyrin-Associated Periodic Syndrome (CAPS) Report Insights
- Cryopyrin-Associated Periodic Syndrome (CAPS) Pipeline Analysis
- Therapeutic Assessment
- Unmet Needs
- Impact of Drugs
- Pipeline Product Profiles
- Therapeutic Assessment
- Pipeline Assessment
- Inactive drugs assessment
- Unmet Needs
Current Treatment Scenario and Emerging Therapies:
- How many companies are developing Cryopyrin-Associated Periodic Syndrome (CAPS) drugs?
- How many Cryopyrin-Associated Periodic Syndrome (CAPS) drugs are developed by each company?
- How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Cryopyrin-Associated Periodic Syndrome (CAPS)?
- What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Cryopyrin-Associated Periodic Syndrome (CAPS) therapeutics?
- What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
- What are the clinical studies going on for Cryopyrin-Associated Periodic Syndrome (CAPS) and their status?
- What are the key designations that have been granted to the emerging drugs?
- Novartis
- Inflazome
- Mabpharm
- Roche
- DFV 890
- IZD 334
- Inzomelid
- CMAB 816
Introduction
Executive Summary
Cryopyrin-Associated Periodic Syndrome (CAPS): Overview
Causes
Mechanism of Action
Signs and Symptoms
Diagnosis
Disease Management
Pipeline Therapeutics
Comparative Analysis
Therapeutic Assessment
Assessment by Product Type
Assessment by Stage and Product Type
Assessment by Route of Administration
Assessment by Stage and Route of Administration
Assessment by Molecule Type
Assessment by Stage and Molecule Type
Mid Stage Products (Phase II)
Comparative Analysis
DFV 890: Novartis
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Early Stage Products (Phase I)
Comparative Analysis
IZD 334: Inflazome
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Inactive Products
Comparative Analysis
Cryopyrin-Associated Periodic Syndrome (CAPS) Key Companies
Cryopyrin-Associated Periodic Syndrome (CAPS) Key Products
Cryopyrin-Associated Periodic Syndrome (CAPS)- Unmet Needs
Cryopyrin-Associated Periodic Syndrome (CAPS)- Market Drivers and Barriers
Cryopyrin-Associated Periodic Syndrome (CAPS)- Future Perspectives and Conclusion
Cryopyrin-Associated Periodic Syndrome (CAPS) Analyst Views
Cryopyrin-Associated Periodic Syndrome (CAPS) Key Companies
Appendix
Executive Summary
Cryopyrin-Associated Periodic Syndrome (CAPS): Overview
Causes
Mechanism of Action
Signs and Symptoms
Diagnosis
Disease Management
Pipeline Therapeutics
Comparative Analysis
Therapeutic Assessment
Assessment by Product Type
Assessment by Stage and Product Type
Assessment by Route of Administration
Assessment by Stage and Route of Administration
Assessment by Molecule Type
Assessment by Stage and Molecule Type
Mid Stage Products (Phase II)
Comparative Analysis
DFV 890: Novartis
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Early Stage Products (Phase I)
Comparative Analysis
IZD 334: Inflazome
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Inactive Products
Comparative Analysis
Cryopyrin-Associated Periodic Syndrome (CAPS) Key Companies
Cryopyrin-Associated Periodic Syndrome (CAPS) Key Products
Cryopyrin-Associated Periodic Syndrome (CAPS)- Unmet Needs
Cryopyrin-Associated Periodic Syndrome (CAPS)- Market Drivers and Barriers
Cryopyrin-Associated Periodic Syndrome (CAPS)- Future Perspectives and Conclusion
Cryopyrin-Associated Periodic Syndrome (CAPS) Analyst Views
Cryopyrin-Associated Periodic Syndrome (CAPS) Key Companies
Appendix
LIST OF TABLES
Table 1 Total Products for Cryopyrin-Associated Periodic Syndrome (CAPS)
Table 2 Late Stage Products
Table 3 Mid Stage Products
Table 4 Early Stage Products
Table 5 Pre-clinical & Discovery Stage Products
Table 6 Assessment by Product Type
Table 7 Assessment by Stage and Product Type
Table 8 Assessment by Route of Administration
Table 9 Assessment by Stage and Route of Administration
Table 10 Assessment by Molecule Type
Table 11 Assessment by Stage and Molecule Type
Table 12 Inactive Products
Table 1 Total Products for Cryopyrin-Associated Periodic Syndrome (CAPS)
Table 2 Late Stage Products
Table 3 Mid Stage Products
Table 4 Early Stage Products
Table 5 Pre-clinical & Discovery Stage Products
Table 6 Assessment by Product Type
Table 7 Assessment by Stage and Product Type
Table 8 Assessment by Route of Administration
Table 9 Assessment by Stage and Route of Administration
Table 10 Assessment by Molecule Type
Table 11 Assessment by Stage and Molecule Type
Table 12 Inactive Products
LIST OF FIGURES
Figure 1 Total Products for Cryopyrin-Associated Periodic Syndrome (CAPS)
Figure 2 Late Stage Products
Figure 3 Mid Stage Products
Figure 4 Early Stage Products
Figure 5 Preclinical and Discovery Stage Products
Figure 6 Assessment by Product Type
Figure 7 Assessment by Stage and Product Type
Figure 8 Assessment by Route of Administration
Figure 9 Assessment by Stage and Route of Administration
Figure 10 Assessment by Molecule Type
Figure 11 Assessment by Stage and Molecule Type
Figure 12 Inactive Products
Figure 1 Total Products for Cryopyrin-Associated Periodic Syndrome (CAPS)
Figure 2 Late Stage Products
Figure 3 Mid Stage Products
Figure 4 Early Stage Products
Figure 5 Preclinical and Discovery Stage Products
Figure 6 Assessment by Product Type
Figure 7 Assessment by Stage and Product Type
Figure 8 Assessment by Route of Administration
Figure 9 Assessment by Stage and Route of Administration
Figure 10 Assessment by Molecule Type
Figure 11 Assessment by Stage and Molecule Type
Figure 12 Inactive Products